Associated Press September 27, 2018
After two failed buyout attempts that could have put it in
a better position to compete against larger rivals, Rite Aid is shuffling its
board of directors and dividing power at the top of the drugstore chain.
Rite Aid said Thursday that three new, independent
directors will be nominated to its board and that CEO John Standley will no
longer hold the title of chairman. That goes to current board member Bruce
Bodaken.
Shareholders will vote next month on whether to approve
new board nominees Robert Knowling Jr., Louis Miramontes and Arun Nayar. They
would replace current directors David Jessick, Myrtle Potter and Frank Savage.
The company accelerated a board shake-up after speaking
with shareholders in the wake a failed buyout attempt by the grocer Albertsons,
Bodaken said in a prepared statement.
The collapse of the Albertson's deal followed another
proposed buyout, from Walgreens, which ended the same way. Walgreens eventually
agreed to buy nearly 2,000 stores from Rite Aid Corp.
Rite Aid, after the sale of its stores, has about 2,500
locations located mostly on the East and West coasts, as well as a pharmacy
benefit management business that runs prescription drug coverage.
It planned to pare off more of those assets in a separate
sale to Albertsons, but called off that deal before a shareholder vote last
month. It had already received bad reviews from two prominent shareholder
advisory firms and one of the drugstore chain's biggest stock owners,
Highfields Capital Management.
A couple days before it quashed the sale, the Camp Hill,
Pennsylvania, company slashed its annual earnings forecast.
Rite Aid is trying to hold off bigger rivals like
Walgreens or CVS Health Corp., and it's not getting any easier. CVS is spending
around $69 billion to acquire the health insurer Aetna Inc.
Rite Aid on Thursday put up second-quarter earnings that
did not impress Wall Street and shares, down more than 30 percent this year,
slipped again in early trading.
No comments:
Post a Comment